# US 2022/0009905 A1 · Map kinase modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009905 A1
- Document ID: US20220009905A1
- Status: Published application
- Kind: A1
- Application number: 17/476,648
- Filed: 2021-09-16
- Published: 2022-01-13
- Earliest claimed: 2013-03-15
- Assignees: The Trustees of Columbia University in the City of New York; Northwestern University
- Applicants: The Trustees of Columbia University in the City of New York; Northwestern University
- Inventors: Ottavio ARANCIO; Daniel Martin WATTERSON; Jeffrey Claude PELLETIER; Saktimayee Mitra ROY
- Web page: https://patentgrep.com/patent/US20220009905A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38α MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

## Claims

### Claim 1

A method of treating amyotrophic lateral sclerosis in a subject comprising administration of a therapeutically effective amount of a compound of formula (I), or a composition comprising a compound of formula (I),
wherein
X1 is N and X2 is CH, or X1 is CH and X2 is N;
R1 is —N(R4)2, cyclopropyl, or R5-piperidin-4-yl;
R2 is independently D or halogen;
R3 is naphthyl, quinolinyl, or isoquinolinyl, wherein said naphthyl, quinolinyl, or isoquinolinyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D;
R4 is independently H, (C1-C4)-alkyl, (C1-C4)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S, and wherein the 3-7 membered heterocyclic ring is optionally substituted with a (C1-C3)-alkyl;
R5 is H or (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D;
R6 is H, (C1-C3)-alkyl, (C1-C3)-alkyl substituted with at least one D, or pyrimidin-2-yl; and
n is an integer from 0-4; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
R4 is independently H, (C1-C3)-alkyl, (C1-C3)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S; and
R6 is H, (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D.

### Claim 3 (depends on 2)

The method of claim 2, wherein:
R3 is naphthyl, quinolinyl, or isoquinolinyl, wherein said naphthyl, quinolinyl, or isoquinolinyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is selected from

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is
